Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Giulia Tasca"'
Autor:
Maria Vittoria Dieci, Gaia Griguolo, Michele Bottosso, Vassilena Tsvetkova, Carlo Alberto Giorgi, Grazia Vernaci, Silvia Michieletto, Silvia Angelini, Alberto Marchet, Giulia Tasca, Elisa Genovesi, Enrico Cumerlato, Marcello Lo Mele, PierFranco Conte, Valentina Guarneri
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-7 (2021)
Abstract Although 1% is the recommended cut-off to define estrogen receptor (ER) positivity, a 10% cut-off is often used in clinical practice for therapeutic purposes. We here evaluate clinical outcomes according to ER levels in a monoinstitutional c
Externí odkaz:
https://doaj.org/article/a5d10581508547cdb6d83e4a415f9496
Autor:
Giulia Tasca, Maria Vittoria Dieci, Zora Baretta, Giovanni Faggioni, Marco Montagna, Maria Ornella Nicoletto, Fedro Alessandro Peccatori, Valentina Guarneri, Nicoletta Colombo
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
PurposeWe aimed to evaluate the clinico-pathological characteristics and survival outcomes of patients with synchronous or metachronous breast cancer (BC) and ovarian cancer (OC).Materials and MethodsPatients with synchronous or metachronous BC and O
Externí odkaz:
https://doaj.org/article/5b6bf68058b4418aa1e756b420136b35
Autor:
Maria Vittoria Dieci, Valentina Guarneri, Angelo Paolo Dei Tos, PierFranco Conte, Elisabetta Di Liso, Michele Bottosso, Marcello Lo Mele, Vassilena Tsvetkova, Federica Miglietta, Cristina Falci, Giovanni Faggioni, Giulia Tasca, Carlo Alberto Giorgi, Tommaso Giarratano, Eleonora Mioranza, Silvia Michieletto, Tania Saibene
Publikováno v:
ESMO Open, Vol 5, Iss 5 (2020)
Background Phyllodes tumours (PTs) are rare fibroepithelial tumours accounting for 5 cm vs T≤2 cm). Higher tumour-infiltrating lymphocytes (TILs) were associated with borderline and malignant PT (p=0.023); TILs were not associated with phyllodes-re
Externí odkaz:
https://doaj.org/article/e3c7c72bd29746509cfeb4fa9974d264
Autor:
Maria Vittoria Dieci, Vassilena Tsvetkova, Enrico Orvieto, Federico Piacentini, Guido Ficarra, Gaia Griguolo, Federica Miglietta, Tommaso Giarratano, Claudia Omarini, Serena Bonaguro, Rocco Cappellesso, Camillo Aliberti, Grazia Vernaci, Carlo Alberto Giorgi, Giovanni Faggioni, Giulia Tasca, Pierfranco Conte, Valentina Guarneri
Publikováno v:
Breast Cancer Research, Vol 20, Iss 1, Pp 1-10 (2018)
Abstract Background Tumor-infiltrating lymphocytes (TILs) evaluated in primary breast cancer (BC) convey prognostic information. Limited data in the metastatic setting are available. Methods Secondary lesions from 94 BC patients, 43 triple-negative (
Externí odkaz:
https://doaj.org/article/51b715e5259a4aa8aa3035d2ff94fc36
Autor:
Maria Vittoria Dieci, Vassilena Tsvetkova, Gaia Griguolo, Federica Miglietta, Mara Mantiero, Giulia Tasca, Enrico Cumerlato, Carlo Alberto Giorgi, Tommaso Giarratano, Giovanni Faggioni, Cristina Falci, Grazia Vernaci, Alice Menichetti, Eleonora Mioranza, Elisabetta Di Liso, Simona Frezzini, Tania Saibene, Enrico Orvieto, Valentina Guarneri
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Background: We evaluated immunohistochemical AR expression and correlation with prognosis in a large series of homogeneously treated patients with primary TNBC.Material and Methods: Patients diagnosed with stage I-III TNBC between 2000 and 2015 at Is
Externí odkaz:
https://doaj.org/article/191b8ee17af74b7d9a6e9729c3d812d8
Autor:
Giulia Tasca, Francesca Stella Mosimann, Beatrice Benetti, Simona Frezzini, Valentina Montan, Christian Zurlo, Fabio Girardi, Valentina Guarneri
Publikováno v:
Ovarian cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79fff5fca3e80d1d4742807963833f03
https://doi.org/10.1136/ijgc-2022-esgo.606
https://doi.org/10.1136/ijgc-2022-esgo.606
Autor:
Carlo Alberto Giorgi, Michele Bottosso, Marcello Lo Mele, Vassilena Tsvetkova, Pierfranco Conte, Enrico Cumerlato, Silvia Angelini, Valentina Guarneri, Maria Vittoria Dieci, Giulia Tasca, Gaia Griguolo
Publikováno v:
Cancer Research. 80:P3-08
Background: Although 1% is recommended by guidelines as cut-off for estrogen receptor (ER) positivity, the 10% cut-off is often used in clinical practice based on studies showing that breast cancers with ER ≥1% & DFS and OS Hazard Ratios for ER≥1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d87d5ecf83d89ca37ec2946c274692fa
https://doi.org/10.1158/1538-7445.sabcs19-p3-08-05
https://doi.org/10.1158/1538-7445.sabcs19-p3-08-05
Autor:
Nicoletta Colombo, Federica Tomao, Pierluigi Benedetti Panici, Maria Ornella Nicoletto, Germana Tognon, Alessandra Bologna, Andrea Alberto Lissoni, Andrea DeCensi, Mariateresa Lapresa, Rosanna Mancari, Innocenza Palaia, Giulia Tasca, Francesca Tettamanzi, Maria Francesca Alvisi, Eliana Rulli, Davide Poli, Luciano Carlucci, Valter Torri, Roldano Fossati, Elena Biagioli
Background: Previous findings showed that cediranib-olaparib increased PFS in women with recurrent platinum-sensitive ovarian cancer compared to olaparib alone. Methods: BAROCCO trial randomized 123 patients: 80 mg/m2 paclitaxel weekly up to 24 weeks
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a50894eb2b17531be40c0f3ed8a7a185
http://hdl.handle.net/11573/1643684
http://hdl.handle.net/11573/1643684
Autor:
Elisabetta Di Liso, Cristina Ghiotto, Valentina Guarneri, Gaia Griguolo, Giovanni Faggioni, Grazia Vernaci, Tommaso Giarratano, Maria Vittoria Dieci, Michele Gangemi, Giulia Tasca, Carlo Alberto Giorgi, Carlo Saccardi, Pierfranco Conte, Caterina Barbieri, Alfonso M. Pluchinotta
Publikováno v:
Journal of Women's Health
Background: In the last decades, long-term outcomes of breast cancer (BC) patients have improved, raising new survivorship issues, including fertility preservation and safety of pregnancy after BC. This study assesses evolution in patterns of fertili
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1864af1b0e1058f3469898c8fa6bb1f1
https://doi.org/10.1089/jwh.2018.6986
https://doi.org/10.1089/jwh.2018.6986
Autor:
Carlo Alberto Giorgi, Federica Miglietta, MV Dieci, Gaia Griguolo, Eleonora Mioranza, Pierfranco Conte, Tommaso Giarratano, Giovanni Faggioni, M Mantiero, C Ghiotto, Grazia Vernaci, Silvia Angelini, Cristina Falci, Giulia Tasca, Valentina Guarneri, Simona Frezzini, Alice Menichetti
Publikováno v:
Cancer Research. 79:P6-18
Background: Trastuzumab + pertuzumab + taxane and ado-trastuzumab emtansine (T-DM1) are standard first and second-line therapies for HER2+ metastatic breast cancer. Lapatinib is approved in combination with capecitabine in trastuzumab-resistant patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e847d3a02587e2390ff34ec6f3130b8d
https://doi.org/10.1158/1538-7445.sabcs18-p6-18-24
https://doi.org/10.1158/1538-7445.sabcs18-p6-18-24